Celularity (CELUW) Return on Capital Employed (2019 - 2025)
Celularity (CELUW) reported Return on Capital Employed of 64.17% for Q4 2025, down 1441.0% year-over-year from 4.79% in Q4 2024, and up 31.31% quarter-over-quarter from 93.42% in Q3 2025.
Celularity (CELUW) Return on Capital Employed (2019 - 2025) Analysis & Trends
Celularity (CELUW) has 7 years of Return on Capital Employed data on file, last reported at 64.17% in Q4 2025.
- Return on Capital Employed for Q4 2025 came in at 64.17%, down 1441.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 64.17% (down 1441.0% YoY), and the FY2025 annual result was 49.09%, down 376.0% from the prior year.
- Return on Capital Employed advanced to 64.17% in Q4 2025 per CELUW's latest filing, from 93.42% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 7.17% in Q4 2022 and troughed at 231.0% in Q4 2023.
- A 5-year average of 66.09% and a median of 44.07% in 2021 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed tumbled 22383 bps in 2023, then surged 18123 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 26.93% in 2021, then surged by 73 bps to 7.17% in 2022, then tumbled by 3121 bps to 231.0% in 2023, then jumped by 78 bps to 49.76% in 2024, then dropped by 29 bps to 64.17% in 2025.
- Business Quant data shows CELUW's Return on Capital Employed at 64.17% in Q4 2025, 93.42% in Q3 2025, and 85.19% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Celularity | - | - | -3.27 Mn | -64.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -64.17% |
| Sep 30, 2025 | -93.42% |
| Jun 30, 2025 | -85.19% |
| Mar 31, 2025 | -57.52% |
| Dec 31, 2024 | -49.76% |
| Sep 30, 2024 | -28.15% |
| Jun 30, 2024 | -144.23% |
| Mar 31, 2024 | -174.52% |
| Dec 31, 2023 | -231.00% |
| Sep 30, 2023 | -160.55% |
| Jun 30, 2023 | -39.47% |
| Mar 31, 2023 | -15.18% |
| Dec 31, 2022 | -7.17% |
| Sep 30, 2022 | -15.94% |
| Jun 30, 2022 | -10.40% |
| Mar 31, 2022 | -26.69% |
| Dec 31, 2021 | -26.93% |
| Sep 30, 2021 | -32.05% |
| Jun 30, 2021 | -48.68% |
| Mar 31, 2021 | -10.76% |